PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: implications for CNS disease therapeutics

This study provides unique insight into the selective use of PARP inhibitors to treat neurodegenerative disorders whereby inhibition of PARP enzymatic activity must occur without deleteriously trapping PARP onto DNA.PMID:33631119 | DOI:10.1016/j.neuropharm.2021.108502

Source: Neuropharmacology - February 25, 2021 Category: Drugs & Pharmacology Authors: Asha Sinha Sachin Katyal Tiina M Kauppinen Source Type: research